pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2024-4305pulmo-4305Research ArticleОБЗОРЫREVIEWПрименение ингаляций оксида азота при COVID-19Use of inhaled nitric oxide in COVID-19https://orcid.org/0000-0003-3353-0537НгуенХ. К.NguyenH. C.

Нгуен Хоанг Кыонг – аспирант кафедры госпитальной терапии педиатрического факультета

117997, Москва, ул. Островитянова, 1

тел.: (967) 203-42-77

Hoang Cuong Nguyen, Postgraduate student, Department of Hospital Therapy, Pediatric Faculty

ul. Ostrovityanova 1, Moscow, 117997

tel.: (967) 203-42-77

drcuong@mail.ruhttps://orcid.org/0000-0002-7410-4297ПоздняковаД. Д.PozdnyakovaD. D.

Позднякова Дарья Дмитриевна – ассистент, аспирант кафедры госпитальной терапии педиатрического факультета

117997, Москва, ул. Островитянова, 1

тел.: (910) 343-38-70

Darya D. Pozdnyakova, Assistant, Graduate student, Department of Hospital Therapy, Pediatric Faculty

ul. Ostrovityanova 1, Moscow, 117997

tel.: (910) 343-38-70

daryapozdn@yandex.ruhttps://orcid.org/0000-0002-2469-7346БарановаИ. А.BaranovaI. A.

Баранова Ирина Александровна – д. м. н., профессор, профессор кафедры госпитальной терапии педиатрического факультета

117997, Москва, ул. Островитянова, 1

тел.: (499) 780-08-16

Irina A. Baranova, Doctor of Medicine, Professor, Professor of Hospital Therapy Department, Pediatric Faculty

ul. Ostrovityanova 1, Moscow, 117997

tel.: (499) 780-08-16

iribaranova@yandex.ruhttps://orcid.org/0000-0002-5070-5450ЧучалинА. Г.ChuchalinA. G.

Чучалин Александр Григорьевич – д. м. н., профессор, академик Российской академии наук, заведующий кафедрой госпитальной терапии педиатрического факультета; председатель правления Российского респираторного общества

117997, Москва, ул. Островитянова, 1

тел.: (499) 780-08-50

Alexander G. Chuchalin, Doctor of Medicine, Professor, Academician of Russian Academy of Sciences, Head of Department of Hospital Internal Medicine, Pediatric Faculty; Chairman of the Executive Board of Russian Respiratory Society

ul. Ostrovityanova 1, Moscow, 117997

tel.: (499) 780-08-50

pulmomoskva@mail.ruФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Autonomous Educational Institution of Higher Education “N.I.Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian FederationRussian Federation202409022024343454463Copyright © Нгуен Х.К., Позднякова Д.Д., Баранова И.А., Чучалин А.Г., 20242024Нгуен Х.К., Позднякова Д.Д., Баранова И.А., Чучалин А.Г.Nguyen H.C., Pozdnyakova D.D., Baranova I.A., Chuchalin A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/4305

Ингаляционный оксид азота (iNO) благодаря своим свойствам оказывать противовирусное, антитромботическое и противовоспалительное действие, а также способности расширять кровеносные сосуды предлагается в качестве потенциального метода лечения COVID-19 (CoronaVIrusDisease 2019) и постковидного синдрома (ПКС). В настоящее время недостаточно ясными остаются вопросы селекции пациентов для лечения, а также подбора оптимальной дозировки iNO, продолжительности и времени его введения, а также способы его доставки. Эти факторы могут значительно повлиять на эффективность iNO-терапии.Целью работы явились обсуждение физиологических основ использования iNO в лечении пациентов с COVID-19 и ПКС, анализ результатов проведенных исследований и демонстрация достижений в технике синтеза NO в медицине.Заключение. Показано, что раннее назначение и использование высоких доз iNO представляется эффективным и безопасным методом лечения пациентов с COVID-19, поскольку направлено на основные патобиологические механизмы заболевания. iNO также может быть эффективен у пациентов с ПКС. Однако требуется дальнейшее изучение оптимального (непрерывного или прерывистого) режима дозирования. Последние достижения в области синтеза NO имеют большое значение для широкого практического применения терапии iNO.

Inhaled nitric oxide (iNO) is being considered as a potential therapeutic intervention for COVID-19 and post-COVID syndrome due to its various mechanisms such as vasodilation, antiviral activity, antithrombotic and anti-inflammatory effects. There is currently a lack of information on patient selection criteria, optimal dosing, duration and timing of administration, and methods of administration. These factors are of substantial importance for the efficacy of iNO therapy.Aim. To discuss the physiological basis of using inhaled nitric oxide for treating patients with COVID-19 and post- COVID syndrome, analyze the research findings, and present the achievements in nitric oxide synthesis technology in medicine.Conclusion. The early initiation and use of high-dose iNO appears to be an effective and safe treatment strategy for patients with COVID-19, as it targets the basic pathological mechanisms of the disease. iNO may also be a promising therapeutic option for patients with post-COVID syndrome. However, the optimal dosing regimen, continuous or intermittent, warrants further investigation. Recent advances in nitric oxide synthesis technology are of great significance for the broad practical application of iNO therapy.

оксид азотаингаляция оксида азотаCOVID-19постковидный синдромлечениесинтез оксида азотаnitric oxideinhaled nitric oxideCOVID-19post-COVID syndrometreatmentnitric oxide synthesisReferencesIgnarro L.J. Nitric Oxide. Reference module in biomedical sciences. Elsevier; 2014. DOI: 10.1016/B978-0-12-801238-3.00245-2.Ignarro L.J. Nitric Oxide. Reference module in biomedical sciences. Elsevier; 2014. DOI: 10.1016/B978-0-12-801238-3.00245-2.Nikolaidis A., Kramer R., Ostojic S. Nitric Oxide: the missing factor in COVID-19 severity? Med. Sci. (Basel). 2022; 10 (1): 3. DOI: 10.3390/medsci10010003.Nikolaidis A., Kramer R., Ostojic S. Nitric Oxide: the missing factor in COVID-19 severity? Med. Sci. (Basel). 2022; 10 (1): 3. DOI: 10.3390/medsci10010003.Kapil V., Khambata R.S., Jones D.A. et al. The noncanonical pathway for in vivo nitric oxide generation: the nitrate-nitrite-nitric oxide pathway. Pharmacol. Rev. 2020; 72 (3): 692–766. DOI: 10.1124/pr.120.019240.Kapil V., Khambata R.S., Jones D.A. et al. The noncanonical pathway for in vivo nitric oxide generation: the nitrate-nitrite-nitric oxide pathway. Pharmacol. Rev. 2020; 72 (3): 692–766. DOI: 10.1124/pr.120.019240.Гуманова Н. Оксид азота, его циркулирующие метаболиты NOx и их роль в функционировании человеческого организма и прогнозе риска сердечно-сосудистой смерти (часть I). Профилактическая медицина. 2021; 24 (9): 102–109. DOI: 10.17116/profmed202124091102. / Gumanova N. [Nitric oxide and its circulating NOx metabolites, their role in human body functioning and cardiovascular death risk prediction (part I).]. Profilakticheskaya meditsina. 2021; 24 (9): 102–109. DOI: 10.17116/profmed202124091102 (in Russian).Гуманова Н. Оксид азота, его циркулирующие метаболиты NOx и их роль в функционировании человеческого организма и прогнозе риска сердечно-сосудистой смерти (часть I). Профилактическая медицина. 2021; 24 (9): 102–109. DOI: 10.17116/profmed202124091102. / Gumanova N. [Nitric oxide and its circulating NOx metabolites, their role in human body functioning and cardiovascular death risk prediction (part I).]. Profilakticheskaya meditsina. 2021; 24 (9): 102–109. DOI: 10.17116/profmed202124091102 (in Russian).Lundberg J., Weitzberg E. Nasal nitric oxide in man. Thorax. 1999; 54 (10): 947–952. DOI: 10.1136/thx.54.10.947.Lundberg J., Weitzberg E. Nasal nitric oxide in man. Thorax. 1999; 54 (10): 947–952. DOI: 10.1136/thx.54.10.947.Bryan N.S., Lancaster J.R. Nitric oxide signaling in health and disease. In: Bryan N.S., Loscalzo J., eds. Nitrite and nitrate in human health and disease. Cham: Springer; 2017: 165–178. DOI: 10.1007/978-3-319-46189-2_23.Bryan N.S., Lancaster J.R. Nitric oxide signaling in health and disease. In: Bryan N.S., Loscalzo J., eds. Nitrite and nitrate in human health and disease. Cham: Springer; 2017: 165–178. DOI: 10.1007/978-3-319-46189-2_23.Meng H., Xiong R., He R. et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J. Infect. 2020; 81 (1): e33–39. DOI: 10.1016/j.jinf.2020.04.004.Meng H., Xiong R., He R. et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J. Infect. 2020; 81 (1): e33–39. DOI: 10.1016/j.jinf.2020.04.004.Tzotzos S.J., Fischer B., Fischer H., Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit. Care. 2020; 24 (1): 516. DOI: 10.1186/s13054-020-03240-7.Tzotzos S.J., Fischer B., Fischer H., Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit. Care. 2020; 24 (1): 516. DOI: 10.1186/s13054-020-03240-7.Lan J., Ge J., Yu J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581 (7807): 215–220. DOI: 10.1038/s41586-020-2180-5.Lan J., Ge J., Yu J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581 (7807): 215–220. DOI: 10.1038/s41586-020-2180-5.Ackermann M., Verleden S.E., Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 2020; 383 (2): 120–128. DOI: 10.1056/NEJMoa2015432.Ackermann M., Verleden S.E., Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 2020; 383 (2): 120–128. DOI: 10.1056/NEJMoa2015432.Dominic P., Ahmad J., Bhandari R. et al. Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19. Redox Biol. 2021; 43: 101982. DOI: 10.1016/j.redox.2021.101982.Dominic P., Ahmad J., Bhandari R. et al. Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19. Redox Biol. 2021; 43: 101982. DOI: 10.1016/j.redox.2021.101982.Montiel V., Lobysheva I., Gerard L. et al. Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine. 2022; 77: 103893. DOI: 10.1016/j.ebiom.2022.103893.Montiel V., Lobysheva I., Gerard L. et al. Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine. 2022; 77: 103893. DOI: 10.1016/j.ebiom.2022.103893.Yu B., Ichinose F., Bloch D.B., Zapol W.M. Inhaled nitric oxide. Br. J. Pharmacol. 2019; 176 (2): 246–255. DOI: 10.1111/bph.14512.Yu B., Ichinose F., Bloch D.B., Zapol W.M. Inhaled nitric oxide. Br. J. Pharmacol. 2019; 176 (2): 246–255. DOI: 10.1111/bph.14512.Signori D., Magliocca A., Hayashida K. et al. Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases. Intensive Care Med. Exp. 2022; 10 (1): 28. DOI: 10.1186/s40635-022-00455-6.Signori D., Magliocca A., Hayashida K. et al. Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases. Intensive Care Med. Exp. 2022; 10 (1): 28. DOI: 10.1186/s40635-022-00455-6.Chen L., Liu P., Gao H. et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin. Infect. Dis. 2004; 39 (10): 1531–1535. DOI: 10.1086/425357.Chen L., Liu P., Gao H. et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin. Infect. Dis. 2004; 39 (10): 1531–1535. DOI: 10.1086/425357.Keyaerts E., Vijgen L., Chen L. et al. Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. Int. J. Infect. Dis. 2004; 8 (4): 223–226. DOI: 10.1016/j.ijid.2004.04.012.Keyaerts E., Vijgen L., Chen L. et al. Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. Int. J. Infect. Dis. 2004; 8 (4): 223–226. DOI: 10.1016/j.ijid.2004.04.012.Akerström S., Gunalan V., Keng C.T. et al. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology. 2009; 395 (1): 1–9. DOI: 10.1016/j.virol.2009.09.007.Akerström S., Gunalan V., Keng C.T. et al. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology. 2009; 395 (1): 1–9. DOI: 10.1016/j.virol.2009.09.007.Siddiqi H.K., Mehra M.R. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J. Heart Lung Transplant. 2020; 39 (5): 405–407. DOI: 10.1016/j.healun.2020.03.012.Siddiqi H.K., Mehra M.R. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J. Heart Lung Transplant. 2020; 39 (5): 405–407. DOI: 10.1016/j.healun.2020.03.012.Tamminen P.J., Kerimov D.M., Viskari H. et al. Nasal nitric oxide is decreased in acute mild COVID-19 and related to viral load. J. Breath Res. 2022; 16 (4): 046003. DOI: 10.1088/1752-7163/ac7d6a.Tamminen P.J., Kerimov D.M., Viskari H. et al. Nasal nitric oxide is decreased in acute mild COVID-19 and related to viral load. J. Breath Res. 2022; 16 (4): 046003. DOI: 10.1088/1752-7163/ac7d6a.Farsalinos K., Bagos P.G., Giannouchos T. et al. Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct. J. 2021; 18 (1): 9. DOI: 10.1186/s12954-020-00437-5.Farsalinos K., Bagos P.G., Giannouchos T. et al. Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct. J. 2021; 18 (1): 9. DOI: 10.1186/s12954-020-00437-5.Tandon M., Wu W., Moore K. et al. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: a randomized trial. Lancet Reg. Health Southeast Asia. 2022; 3: 100036. DOI: 10.1016/j.lansea.2022.100036.Tandon M., Wu W., Moore K. et al. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: a randomized trial. Lancet Reg. Health Southeast Asia. 2022; 3: 100036. DOI: 10.1016/j.lansea.2022.100036.Fakhr B.S., Di Fenza R., Gianni S. et al. Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide. 2021; 116: 7–13. DOI: 10.1016/j.niox.2021.08.003.Fakhr B.S., Di Fenza R., Gianni S. et al. Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide. 2021; 116: 7–13. DOI: 10.1016/j.niox.2021.08.003.Parikh R., Wilson C., Weinberg J. et al. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Ther. Adv. Respir. Dis. 2020; 14: 1753466620933510. DOI: 10.1177/1753466620933510.Parikh R., Wilson C., Weinberg J. et al. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Ther. Adv. Respir. Dis. 2020; 14: 1753466620933510. DOI: 10.1177/1753466620933510.Valsecchi C., Winterton D., Safaee Fakhr B. et al. High-dose inhaled nitric oxide for the treatment of spontaneously breathing pregnant patients with severe coronavirus disease 2019 (COVID-19) pneumonia. Obstet. Gynecol. 2022; 140 (2): 195–203. DOI: 10.1097/AOG.0000000000004847.Valsecchi C., Winterton D., Safaee Fakhr B. et al. High-dose inhaled nitric oxide for the treatment of spontaneously breathing pregnant patients with severe coronavirus disease 2019 (COVID-19) pneumonia. Obstet. Gynecol. 2022; 140 (2): 195–203. DOI: 10.1097/AOG.0000000000004847.Zamanian R.T., Pollack Jr C.V., Gentile M.A. et al. Outpatient inhaled nitric oxide in a patient with vasoreactive idiopathic pulmonary arterial hypertension and COVID-19 infection. Am. J. Respir. Crit. Care Med. 2020; 202 (1): 130–132. DOI: 10.1164/rccm.202004-0937LE.Zamanian R.T., Pollack Jr C.V., Gentile M.A. et al. Outpatient inhaled nitric oxide in a patient with vasoreactive idiopathic pulmonary arterial hypertension and COVID-19 infection. Am. J. Respir. Crit. Care Med. 2020; 202 (1): 130–132. DOI: 10.1164/rccm.202004-0937LE.Ichinose F., Roberts Jr J.D., Zapol W.M. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004; 109 (25): 3106–3111. DOI: 10.1161/01.CIR.0000134595.80170.62.Ichinose F., Roberts Jr J.D., Zapol W.M. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004; 109 (25): 3106–3111. DOI: 10.1161/01.CIR.0000134595.80170.62.Steudel W., Hurford W.E., Zapol W.M. et al. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology. 1999; 91 (4): 1090–1121. DOI: 10.1097/00000542-199910000-00030.Steudel W., Hurford W.E., Zapol W.M. et al. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology. 1999; 91 (4): 1090–1121. DOI: 10.1097/00000542-199910000-00030.Taylor R.W., Zimmerman J.L., Dellinger R.P. et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004; 291 (13): 1603–1609. DOI: 10.1001/jama.291.13.1603.Taylor R.W., Zimmerman J.L., Dellinger R.P. et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004; 291 (13): 1603–1609. DOI: 10.1001/jama.291.13.1603.Gebistorf F., Karam O., Wetterslev J., Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst. Rev. 2016 (6): CD002787. DOI: 10.1002/14651858.cd002787.pub3.Gebistorf F., Karam O., Wetterslev J., Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst. Rev. 2016 (6): CD002787. DOI: 10.1002/14651858.cd002787.pub3.Prakash A., Kaur S., Kaur C. et al. Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: a systematic review. Indian J. Pharmacol. 2021; 53 (3): 236–243. DOI: 10.4103/ijp.ijp_382_21.Prakash A., Kaur S., Kaur C. et al. Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: a systematic review. Indian J. Pharmacol. 2021; 53 (3): 236–243. DOI: 10.4103/ijp.ijp_382_21.Beitler J.R., Thompson B.T., Baron R.M. et al. Advancing precision medicine for acute respiratory distress syndrome. Lancet Respir. Med. 2021; 10 (1): 107–120. DOI: 10.1016/S2213-2600(21)00157-0.Beitler J.R., Thompson B.T., Baron R.M. et al. Advancing precision medicine for acute respiratory distress syndrome. Lancet Respir. Med. 2021; 10 (1): 107–120. DOI: 10.1016/S2213-2600(21)00157-0.Tavazzi G., Pozzi M., Mongodi S. et al. Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia. Crit. Care. 2020; 24 (1): 508. DOI: 10.1186/s13054-020-03222-9.Tavazzi G., Pozzi M., Mongodi S. et al. Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia. Crit. Care. 2020; 24 (1): 508. DOI: 10.1186/s13054-020-03222-9.Garfield B., McFadyen C., Briar C. et al. Potential for personalised application of inhaled nitric oxide in COVID-19 pneumonia. Br. J. Anaesth. 2021; 126 (2): e72–75. DOI: 10.1016/j.bja.2020.11.006.Garfield B., McFadyen C., Briar C. et al. Potential for personalised application of inhaled nitric oxide in COVID-19 pneumonia. Br. J. Anaesth. 2021; 126 (2): e72–75. DOI: 10.1016/j.bja.2020.11.006.DeGrado J.R., Szumita P.M., Schuler B.R. et al. Evaluation of the efficacy and safety of inhaled epoprostenol and inhaled nitric oxide for refractory hypoxemia in patients with coronavirus disease 2019. Crit. Care Explor. 2020; 2 (10): e0259. DOI: 10.1097/CCE.0000000000000259.DeGrado J.R., Szumita P.M., Schuler B.R. et al. Evaluation of the efficacy and safety of inhaled epoprostenol and inhaled nitric oxide for refractory hypoxemia in patients with coronavirus disease 2019. Crit. Care Explor. 2020; 2 (10): e0259. DOI: 10.1097/CCE.0000000000000259.Davis H.E., McCorkell L., Vogel J.M. et al. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023; 21 (3): 1–14. DOI: 10.1038/s41579-022-00846-2.Davis H.E., McCorkell L., Vogel J.M. et al. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023; 21 (3): 1–14. DOI: 10.1038/s41579-022-00846-2.World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October, 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 [Accessed: May 01, 2023].World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October, 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 [Accessed: May 01, 2023].Wang J., Mei F., Bai L. et al. Serum nitrite and nitrate: a potential biomarker for post-covid-19 complications? Free Radic. Biol. Med. 2021; 175: 216–225. DOI: 10.1016/j.freeradbiomed.2021.08.237.Wang J., Mei F., Bai L. et al. Serum nitrite and nitrate: a potential biomarker for post-covid-19 complications? Free Radic. Biol. Med. 2021; 175: 216–225. DOI: 10.1016/j.freeradbiomed.2021.08.237.Muangritdech N., Hamlin M.J., Sawanyawisuth K. et al. Hypoxic training improves blood pressure, nitric oxide and hypoxia-inducible factor-1 alpha in hypertensive patients. Eur. J. Appl. Physiol. 2020; 120 (8): 1815–1826. DOI: 10.1007/s00421-020-04410-9.Muangritdech N., Hamlin M.J., Sawanyawisuth K. et al. Hypoxic training improves blood pressure, nitric oxide and hypoxia-inducible factor-1 alpha in hypertensive patients. Eur. J. Appl. Physiol. 2020; 120 (8): 1815–1826. DOI: 10.1007/s00421-020-04410-9.ClinicalTrials.gov. Hypoxic-hyperoxic training in patients with cardiovascular pathology after COVID-19 infection. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05379608 [Accessed: May 01, 2023].ClinicalTrials.gov. Hypoxic-hyperoxic training in patients with cardiovascular pathology after COVID-19 infection. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05379608 [Accessed: May 01, 2023].Шейко Г., Исраелян Ю., Белова А. и др. Физиотерапевтические методы в реабилитации пациентов с COVID-19. Вестник физиотерапии и курортологии. 2020; 26 (4): 63–70. Доступно на: https://cyberleninka.ru/article/n/fizioterapevticheskie-metody-v-reabilitatsii-patsientov-s-covid-19?ysclid=ls0ayev7hg948878945 / Shejko G., Israeljan Ju., Belova A. et al. [Physiotherapeutic methods in the rehabilitation of patients with COVID-19]. Vestnik fizioterapii i kurortologii. 2020; 26 (4): 63–70. Available at: https://cyberleninka.ru/article/n/fizioterapevticheskie-metody-v-reabilitatsii-patsientov-s-covid-19?ysclid=ls0ayev7hg948878945 (in Russian).Шейко Г., Исраелян Ю., Белова А. и др. Физиотерапевтические методы в реабилитации пациентов с COVID-19. Вестник физиотерапии и курортологии. 2020; 26 (4): 63–70. Доступно на: https://cyberleninka.ru/article/n/fizioterapevticheskie-metody-v-reabilitatsii-patsientov-s-covid-19?ysclid=ls0ayev7hg948878945 / Shejko G., Israeljan Ju., Belova A. et al. [Physiotherapeutic methods in the rehabilitation of patients with COVID-19]. Vestnik fizioterapii i kurortologii. 2020; 26 (4): 63–70. Available at: https://cyberleninka.ru/article/n/fizioterapevticheskie-metody-v-reabilitatsii-patsientov-s-covid-19?ysclid=ls0ayev7hg948878945 (in Russian).Garnacho-Castaño M.V., Sánchez-Nuño S., Molina-Raya L. et al. Circulating nitrate-nitrite reduces oxygen uptake for improving resistance exercise performance after rest time in well-trained CrossFit athletes. Sci. Rep. 2022; 12 (1): 9671. DOI: 10.1038/s41598-022-13786-x.Garnacho-Castaño M.V., Sánchez-Nuño S., Molina-Raya L. et al. Circulating nitrate-nitrite reduces oxygen uptake for improving resistance exercise performance after rest time in well-trained CrossFit athletes. Sci. Rep. 2022; 12 (1): 9671. DOI: 10.1038/s41598-022-13786-x.Nelin L.D., Potenziano J.L. Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: time to treatment response. BMC Pediatr. 2019; 19 (1): 17. DOI: 10.1186/s12887-018-1368-4.Nelin L.D., Potenziano J.L. Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: time to treatment response. BMC Pediatr. 2019; 19 (1): 17. DOI: 10.1186/s12887-018-1368-4.Abou-Arab O., Huette P., Debouvries F. et al. Inhaled nitric oxide for critically ill COVID-19 patients: a prospective study. Crit. Care. 2020; 24 (1): 645. DOI: 10.1186/s13054-020-03371-x.Abou-Arab O., Huette P., Debouvries F. et al. Inhaled nitric oxide for critically ill COVID-19 patients: a prospective study. Crit. Care. 2020; 24 (1): 645. DOI: 10.1186/s13054-020-03371-x.Chandel A., Patolia S., Ahmad K. et al. Inhaled nitric oxide via high-flow nasal cannula in patients with acute respiratory failure related to COVID-19. Clin. Med. Insights Circ. Respir. Pulm. Med. 2021; 15: 11795484211047065. DOI: 10.1177/11795484211047065.Chandel A., Patolia S., Ahmad K. et al. Inhaled nitric oxide via high-flow nasal cannula in patients with acute respiratory failure related to COVID-19. Clin. Med. Insights Circ. Respir. Pulm. Med. 2021; 15: 11795484211047065. DOI: 10.1177/11795484211047065.Herranz L., da Silveira J.G., Trocado L.F.L. et al. Inhaled nitric oxide in patients with severe COVID-19 infection at intensive care unit – a cross sectional study. J. Crit. Care Med. (Targu Mures). 2021; 7 (4): 318–319. DOI: 10.2478/jccm-2021-0033.Herranz L., da Silveira J.G., Trocado L.F.L. et al. Inhaled nitric oxide in patients with severe COVID-19 infection at intensive care unit – a cross sectional study. J. Crit. Care Med. (Targu Mures). 2021; 7 (4): 318–319. DOI: 10.2478/jccm-2021-0033.Robba C., Ball L., Battaglini D. et al. Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. Crit. Care. 2021; 25 (1): 111. DOI: 10.1186/s13054-021-03537-1.Robba C., Ball L., Battaglini D. et al. Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. Crit. Care. 2021; 25 (1): 111. DOI: 10.1186/s13054-021-03537-1.Lotz C., Muellenbach R.M., Meybohm P. et al. Effects of inhaled nitric oxide in COVID‐19-induced ARDS – is it worthwhile? Acta Anaesthesiol. Scand. 2021; 65 (5): 629–632. DOI: 10.1111/aas.13757.Lotz C., Muellenbach R.M., Meybohm P. et al. Effects of inhaled nitric oxide in COVID‐19-induced ARDS – is it worthwhile? Acta Anaesthesiol. Scand. 2021; 65 (5): 629–632. DOI: 10.1111/aas.13757.Roberts Jr J., Polaner D.M., Zapol W. et al. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992; 340 (8823): 818–819. DOI: 10.1016/0140-6736(92)92686-a.Roberts Jr J., Polaner D.M., Zapol W. et al. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992; 340 (8823): 818–819. DOI: 10.1016/0140-6736(92)92686-a.Miller C., Miller M., McMullin B. et al. A phase I clinical study of inhaled nitric oxide in healthy adults. J. Cyst. Fibros. 2012; 11 (4): 324–331. DOI: 10.1016/j.jcf.2012.01.003.Miller C., Miller M., McMullin B. et al. A phase I clinical study of inhaled nitric oxide in healthy adults. J. Cyst. Fibros. 2012; 11 (4): 324–331. DOI: 10.1016/j.jcf.2012.01.003.Fakhr B.S., Wiegand S.B., Pinciroli R. et al. High concentrations of nitric oxide inhalation therapy in pregnant patients with severe coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2020; 136 (6): 1109–1113. DOI: 10.1097/AOG.0000000000004128.Fakhr B.S., Wiegand S.B., Pinciroli R. et al. High concentrations of nitric oxide inhalation therapy in pregnant patients with severe coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2020; 136 (6): 1109–1113. DOI: 10.1097/AOG.0000000000004128.Каменщиков Н., Кузнецов М., Дьякова М. и др. Ингаляционная терапия коморбидного пациента с COVID-19 высокими дозами оксида азота: клинический случай. Сибирский журнал клинической и экспериментальной медицины. 2022; 37 (4): 180–187. DOI: 10.29001/2073-8552-2022-37-4-180-187. / Kamenshhikov N., Kuznecov M., D'jakova M. et al. [Inhalation therapy of a comorbid patient with COVID-19 with high doses of nitric oxide: a clinical case]. Sibirskiy zhurnal klinicheskoy i eksperimental'noy meditsiny. 2022; 37 (4): 180–187. DOI: 10.29001/2073-8552-2022-37-4-180-187 (in Russian).Каменщиков Н., Кузнецов М., Дьякова М. и др. Ингаляционная терапия коморбидного пациента с COVID-19 высокими дозами оксида азота: клинический случай. Сибирский журнал клинической и экспериментальной медицины. 2022; 37 (4): 180–187. DOI: 10.29001/2073-8552-2022-37-4-180-187. / Kamenshhikov N., Kuznecov M., D'jakova M. et al. [Inhalation therapy of a comorbid patient with COVID-19 with high doses of nitric oxide: a clinical case]. Sibirskiy zhurnal klinicheskoy i eksperimental'noy meditsiny. 2022; 37 (4): 180–187. DOI: 10.29001/2073-8552-2022-37-4-180-187 (in Russian).Gerlach H., Keh D., Semmerow A. et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am. J. Respir. Crit. Care Med. 2003; 167 (7): 1008–1015. DOI: 10.1164/rccm.2108121.Gerlach H., Keh D., Semmerow A. et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am. J. Respir. Crit. Care Med. 2003; 167 (7): 1008–1015. DOI: 10.1164/rccm.2108121.Kamenshchikov N.O., Berra L., Carroll R.W. Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines. 2022; 10 (2): 369. DOI: 10.3390/biomedicines10020369.Kamenshchikov N.O., Berra L., Carroll R.W. Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines. 2022; 10 (2): 369. DOI: 10.3390/biomedicines10020369.Ziehr D.R., Alladina J., Wolf M.E. et al. Respiratory physiology of prone positioning with and without inhaled nitric oxide across the coronavirus disease 2019 acute respiratory distress syndrome severity spectrum. Crit. Care Explor. 2021; 3 (6): e0471. DOI: 10.1097/CCE.0000000000000471.Ziehr D.R., Alladina J., Wolf M.E. et al. Respiratory physiology of prone positioning with and without inhaled nitric oxide across the coronavirus disease 2019 acute respiratory distress syndrome severity spectrum. Crit. Care Explor. 2021; 3 (6): e0471. DOI: 10.1097/CCE.0000000000000471.Pierce C., Peters M., Cohen G. et al. Cost of nitric oxide is exorbitant. BMJ. 2002; 325 (7359): 336. DOI: 10.1136/bmj.325.7359.336.Pierce C., Peters M., Cohen G. et al. Cost of nitric oxide is exorbitant. BMJ. 2002; 325 (7359): 336. DOI: 10.1136/bmj.325.7359.336.Tzanetos D.R.T., Housley J.J., Barr F.E. et al. Implementation of an inhaled nitric oxide protocol decreases direct cost associated with its use. Respir. Care. 2015; 60 (5): 644–650. DOI: 10.4187/respcare.03308.Tzanetos D.R.T., Housley J.J., Barr F.E. et al. Implementation of an inhaled nitric oxide protocol decreases direct cost associated with its use. Respir. Care. 2015; 60 (5): 644–650. DOI: 10.4187/respcare.03308.

The authors declare that there are no conflicts of interest present.